DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
Status:
RECRUITING
Trial end date:
2028-10-31
Target enrollment:
Participant gender:
Summary
This is a Phase 2 Study of DRP-104, a Glutamine Antagonist, in Patients with NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer following standard of care treatment with chemotherapy and immunotherapy.